P2RY12
P2Y purinoceptor 12
As of the edition of 20 October 2026, P2RY12 (P2Y purinoceptor 12, UniProt Q9H244) has 8 drugs tested at it and 13 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9H244
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Heart and blood vessels; Nervous system; Nutrition and metabolism; Hormones; Inherited and neonatal; Blood and lymph; Lungs and airways; Urinary and reproductive
- Registered trials of its drugs
- 725
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Clopidogrel | Marketed | Phase 4 | none listed |
| Ticagrelor | Marketed | Phase 4 | none listed |
| Prasugrel | Marketed | Phase 4 | none listed |
| Cangrelor | Marketed | Phase 4 | none listed |
| Selatogrel | Active | Phase 3 | none listed |
| Elinogrel | Went quiet | Phase 2 | none listed |
| Regrelor | Stopped | Phase 2 | none listed |
| Ticlopidine | Marketed | Phase 4 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 2 |
| Undetermined | 6 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Sanofi | Route B |
| AstraZeneca | Route B |
| Merck & Co. | Route A |
The other 10 companies at P2RY12
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at P2RY12, ranked, with the facts behind eachRequest access. Nothing is shown until you do.